Analyst Ratings For CytomX Therapeutics Inc (NASDAQ:CTMX)
Today, HC Wainwright initiated coverage on CytomX Therapeutics Inc (NASDAQ:CTMX) with a Buy with a price target of $32.00.
There are 9 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on CytomX Therapeutics Inc (NASDAQ:CTMX) is Buy with a consensus target price of $38.8750 per share, a potential 104.82% upside.
Some recent analyst ratings include
- 9/13/2018-CytomX Therapeutics Inc (NASDAQ:CTMX) has coverage initiated with a Buy rating and $32.00 price target
- 6/1/2018-CytomX Therapeutics Inc (NASDAQ:CTMX) has coverage initiated with a Buy rating and $38.00 price target
- 5/10/2018-CytomX Therapeutics Inc (NASDAQ:CTMX) had its Buy rating reiterated by Cowen
- 1/5/2018-CytomX Therapeutics Inc (NASDAQ:CTMX) has coverage initiated with a Buy ➝ Buy rating and $40.00 price target
Recent Insider Trading Activity For CytomX Therapeutics Inc (NASDAQ:CTMX)
CytomX Therapeutics Inc (NASDAQ:CTMX) has insider ownership of 8.50% and institutional ownership of 72.17%.
- On 9/4/2018 Debanjan Ray, CFO, sold 3,000 with an average share price of $22.39 per share and the total transaction amounting to $67,170.00.
- On 9/4/2018 Sean A Mccarthy, Insider, sold 13,052 with an average share price of $21.86 per share and the total transaction amounting to $285,316.72.
- On 8/1/2018 Debanjan Ray, CFO, sold 3,000 with an average share price of $26.05 per share and the total transaction amounting to $78,150.00.
- On 7/5/2018 Sean A Mccarthy, Insider, sold 4,497 with an average share price of $25.06 per share and the total transaction amounting to $112,694.82.
- On 7/3/2018 Sean A Mccarthy, CEO, sold 2,028 with an average share price of $25.09 per share and the total transaction amounting to $50,882.52.
- On 7/2/2018 Debanjan Ray, CFO, sold 3,000 with an average share price of $22.56 per share and the total transaction amounting to $67,680.00.
- On 7/2/2018 Sean A. Mccarthy, Insider, sold 13,052 with an average share price of $23.42 per share and the total transaction amounting to $305,677.84.
About CytomX Therapeutics Inc (NASDAQ:CTMX)
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Recent Trading Activity for CytomX Therapeutics Inc (NASDAQ:CTMX)
Shares of CytomX Therapeutics Inc closed the previous trading session at 18.98 −1.03 5.15% with 19.96 shares trading hands.